EMA imlifidase coverage for business development, investment, and market access teams
Mayer Brown has facilitated SERB Pharmaceuticals' acquisition of European and MENA rights to Idefirix® from Hansa Biopharma AB, marking a significant development in the pharmaceutical landscape.
We use cookies to enhance your experience, analyze traffic, and for marketing. By continuing to use our site, you consent to our use of cookies. Privacy Policy
